Wells Fargo’s Regenxbio RGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $933K | Buy |
77,852
+27,350
| +54% | +$227K | ﹤0.01% | 4159 |
|
|
2026
Q1 | $423K | Sell |
50,502
-34,601
| -41% | -$364K | ﹤0.01% | 4260 |
|
|
2025
Q4 | $1.23M | Buy |
85,103
+11,584
| +16% | +$144K | ﹤0.01% | 3811 |
|
|
2025
Q3 | $709K | Buy |
73,519
+32,142
| +78% | +$284K | ﹤0.01% | 4056 |
|
|
2025
Q2 | $340K | Sell |
41,377
-3,955
| -9% | -$33.1K | ﹤0.01% | 4415 |
|
|
2025
Q1 | $324K | Sell |
45,332
-3,105
| -6% | -$23.1K | ﹤0.01% | 4377 |
|
|
2024
Q4 | $374K | Buy |
48,437
+12,285
| +34% | +$115K | ﹤0.01% | 4379 |
|
|
2024
Q3 | $379K | Buy |
36,152
+1,308
| +4% | +$15.9K | ﹤0.01% | 4170 |
|
|
2024
Q2 | $408K | Buy |
34,844
+5,209
| +18% | +$81.1K | ﹤0.01% | 4041 |
|
|
2024
Q1 | $624K | Buy |
29,635
+3,893
| +15% | +$69.3K | ﹤0.01% | 3745 |
|
|
2023
Q4 | $462K | Sell |
25,742
-10,463
| -29% | -$184K | ﹤0.01% | 3923 |
|
|
2023
Q3 | $596K | Sell |
36,205
-9,843
| -21% | -$178K | ﹤0.01% | 3653 |
|
|
2023
Q2 | $920K | Buy |
46,048
+323
| +0.7% | +$6.22K | ﹤0.01% | 3535 |
|
|
2023
Q1 | $865K | Buy |
45,725
+28,424
| +164% | +$629K | ﹤0.01% | 3478 |
|
|
2022
Q4 | $392K | Sell |
17,301
-7,837
| -31% | -$177K | ﹤0.01% | 3780 |
|
|
2022
Q3 | $665K | Sell |
25,138
-599
| -2% | -$17.8K | ﹤0.01% | 3509 |
|
|
2022
Q2 | $636K | Sell |
25,737
-19,139
| -43% | -$478K | ﹤0.01% | 3592 |
|
|
2022
Q1 | $1.49M | Sell |
44,876
-32,671
| -42% | -$908K | ﹤0.01% | 3556 |
|
|
2021
Q4 | $2.54M | Sell |
77,547
-839
| -1% | -$28.6K | ﹤0.01% | 3243 |
|
|
2021
Q3 | $3.29M | Buy |
78,386
+1,651
| +2% | +$59.4K | ﹤0.01% | 3238 |
|
|
2021
Q2 | $2.98M | Buy |
76,735
+5,932
| +8% | +$212K | ﹤0.01% | 3340 |
|
|
2021
Q1 | $2.42M | Buy |
70,803
+28,453
| +67% | +$1.21M | ﹤0.01% | 3530 |
|
|
2020
Q4 | $1.92M | Buy |
42,350
+7,201
| +20% | +$252K | ﹤0.01% | 3526 |
|
|
2020
Q3 | $967K | Sell |
35,149
-8,035
| -19% | -$262K | ﹤0.01% | 3887 |
|
|
2020
Q2 | $1.59M | Buy |
43,184
+1,038
| +2% | +$38.7K | ﹤0.01% | 3445 |
|
|
2020
Q1 | $1.36M | Sell |
42,146
-46,202
| -52% | -$1.92M | ﹤0.01% | 3316 |
|
|
2019
Q4 | $3.62M | Buy |
88,348
+21,264
| +32% | +$840K | ﹤0.01% | 2852 |
|
|
2019
Q3 | $2.39M | Sell |
67,084
-3,296
| -5% | -$134K | ﹤0.01% | 3181 |
|
|
2019
Q2 | $3.62M | Sell |
70,380
-6,405
| -8% | -$320K | ﹤0.01% | 2854 |
|
|
2019
Q1 | $4.4M | Buy |
76,785
+9,525
| +14% | +$472K | ﹤0.01% | 2681 |
|
|
2018
Q4 | $2.82M | Buy |
67,260
+35,789
| +114% | +$2.1M | ﹤0.01% | 2987 |
|
|
2018
Q3 | $2.38M | Sell |
31,471
-4,182
| -12% | -$301K | ﹤0.01% | 3266 |
|
|
2018
Q2 | $2.56M | Buy |
35,653
+1,954
| +6% | +$93.3K | ﹤0.01% | 3259 |
|
|
2018
Q1 | $1.01M | Sell |
33,699
-1,657
| -5% | -$48.2K | ﹤0.01% | 3915 |
|
|
2017
Q4 | $1.18M | Sell |
35,356
-9,117
| -21% | -$275K | ﹤0.01% | 3820 |
|
|
2017
Q3 | $1.47M | Buy |
44,473
+28,264
| +174% | +$636K | ﹤0.01% | 3557 |
|
|
2017
Q2 | $320K | Buy |
16,209
+175
| +1% | +$3.39K | ﹤0.01% | 4495 |
|
|
2017
Q1 | $309K | Hold |
16,034
| – | – | ﹤0.01% | 4547 |
|
|
2016
Q4 | $297K | Buy |
16,034
+6,290
| +65% | +$120K | ﹤0.01% | 4541 |
|
|
2016
Q3 | $137K | Buy |
9,744
+7,666
| +369% | +$84.6K | ﹤0.01% | 4715 |
|
|
2016
Q2 | $17K | Sell |
2,078
-157
| -7% | -$1.74K | ﹤0.01% | 5531 |
|
|
2016
Q1 | $22K | Buy |
2,235
+157
| +8% | +$2.01K | ﹤0.01% | 5488 |
|
|
2015
Q4 | $34K | Buy |
+2,078
| New | +$41.2K | ﹤0.01% | 5420 |
|
Other funds holding RGNX
RG
Wells Fargo's RGNX Position: Q2 2026 in Review
Wells Fargo increased its Regenxbio (RGNX) stake by 54% in Q2 2026, buying an estimated $227K and bringing the position to 77,852 shares worth $933K. The position accounts for ﹤0.01% of the portfolio, ranked #4159.
Wells Fargo first reported a position in RGNX in Q4 2015 and has held it in 43 quarters since. The position peaked at $4.4M in Q1 2019. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.
- Wells Fargo held 77,852 shares of Regenxbio worth $933K as of Q2 2026.
- Wells Fargo bought 27,350 Regenxbio shares in Q2 2026, an estimated $227K.
- Regenxbio made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4159 holding.
- Wells Fargo first reported a position in Regenxbio in Q4 2015 and has held it in 43 quarters since.
- Wells Fargo's Regenxbio position peaked at $4.4M in Q1 2019.
- 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.